Search hospitals > South Carolina > Greenville
Prisma Health Cancer Institute - Eastside
Claim this profileGreenville, South Carolina 29615
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Non-Small Cell Lung Cancer
308 reported clinical trials
12 medical researchers
Summary
Prisma Health Cancer Institute - Eastside is a medical facility located in Greenville, South Carolina. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Prisma Health Cancer Institute - Eastside is involved with conducting 308 clinical trials across 472 conditions. There are 12 research doctors associated with this hospital, such as Ki Chung, MD, Aniket Saha, Jeffrey K. Giguere, and William J Edenfield, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
Top PIs
Ki Chung, MDPrisma Health Cancer Institute - Eastside5 years of reported clinical research
Expert in Cancer
Expert in Tumors
94 reported clinical trials
192 drugs studied
Aniket SahaBI-LO Charities Children's Cancer Center7 years of reported clinical research
Expert in Brain Tumor
Expert in Tumors
58 reported clinical trials
119 drugs studied
Jeffrey K. GiguerePrisma Health Cancer Institute - Faris7 years of reported clinical research
Studies Cancer
Studies Breast Cancer
26 reported clinical trials
64 drugs studied
William J Edenfield, MDPrisma Health2 years of reported clinical research
Studies Tumors
Studies Cancer
12 reported clinical trials
17 drugs studied
Clinical Trials running at Prisma Health Cancer Institute - Eastside
Breast Cancer
Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Colorectal Cancer
Tumors
Squamous Cell Carcinoma
Rectal Cancer
Colon Cancer
Pancreatic Cancer
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Prisma Health Cancer Institute - Eastside?
Prisma Health Cancer Institute - Eastside is a medical facility located in Greenville, South Carolina. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Prisma Health Cancer Institute - Eastside is involved with conducting 308 clinical trials across 472 conditions. There are 12 research doctors associated with this hospital, such as Ki Chung, MD, Aniket Saha, Jeffrey K. Giguere, and William J Edenfield, MD.